印度德里高等法院允许Reddy博士向无专利国家出口微粒, 驳回Novo Nordisk的上诉。 India's Delhi High Court lets Dr. Reddy’s export semaglutide to patent-free countries, rejecting Novo Nordisk’s appeal.

德里高等法院已允许雷迪博士实验室向诺和诺德无专利的国家出口司美格鲁肽，驳回了诺和诺德关于暂缓执行的上诉。 The Delhi High Court has allowed Dr. Reddy’s Laboratories to export semaglutide to countries where Novo Nordisk holds no patents, rejecting Novo Nordisk’s appeal for a stay. 法院认为丹麦公司的案件软弱无力,支持下级法院的裁决,即该专利缺乏新颖和创造性的步骤。 The court found the Danish company’s case weak and upheld a lower court’s ruling that the patent lacked novelty and inventive step. Reddy博士可能出口该药物,但在印度专利于2026年初到期之前不能销售该药物。 Dr. Reddy’s may export but cannot sell the drug in India until patent expiry in early 2026. 该案定于2026年1月15日最后审理,可能会影响印度未来的非专利药物生产。 The case, set for final hearing on January 15, 2026, could impact future generic drug production in India.